AUTOIMMUNITY
20.9K views | +14 today
AUTOIMMUNITY
Pathology, Diagnosis and Therapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
June 6, 2017 4:42 AM
Scoop.it!

Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers

Neutrophils are well characterized as mediators of peripheral tissue damage in lupus, but it remains unclear whether they influence loss of self-tolerance in the adaptive immune compartment. Lupus neutrophils produce elevated levels of factors known to fuel autoantibody production, including IL-6 and B cell survival factors, but also reactive oxygen intermediates, which can suppress lymphocyte proliferation. To assess whether neutrophils directly influence the progression of autoreactivity in secondary lymphoid organs (SLOs), we characterized the localization and cell–cell contacts of splenic neutrophils at several stages in the progression of disease in the NZB/W murine model of lupus. Neutrophils accumulate in SLO over the course of lupus progression, preferentially localizing near T lymphocytes early in disease and B cells with advanced disease. RNA sequencing reveals that the splenic neutrophil transcriptional program changes significantly over the course of disease, with neutrophil expression of anti-inflammatory mediators peaking during early-stage and midstage disease, and evidence of neutrophil activation with advanced disease. To assess whether neutrophils exert predominantly protective or deleterious effects on loss of B cell self-tolerance in vivo, we depleted neutrophils at different stages of disease. Neutrophil depletion early in lupus resulted in a striking acceleration in the onset of renal disease, SLO germinal center formation, and autoreactive plasma cell production. In contrast, neutrophil depletion with more advanced disease did not alter systemic lupus erythematosus progression. These results demonstrate a surprising temporal and context-dependent role for neutrophils in restraining autoreactive B cell activation in lupus.
No comment yet.
Suggested by Société Francaise d'Immunologie
May 26, 2017 9:58 AM
Scoop.it!

Deficiency of Complement 1r subcomponent in early‐onset SLE: Role for disease‐modifying alleles in a monogenic disease

Deficiency of Complement 1r subcomponent in early‐onset SLE: Role for disease‐modifying alleles in a monogenic disease | AUTOIMMUNITY | Scoop.it
Objective: To identify a genetic cause of early‐onset systemic lupus erythematosus (SLE) in a large consanguineous family from Turkey and to study the mechanisms of disease.Methods: We performe
No comment yet.
Suggested by Société Francaise d'Immunologie
May 23, 2017 11:25 AM
Scoop.it!

Fc Gamma Receptor IIB Deficient Mice: A Lupus Model with In... : Shock

Fc Gamma Receptor IIB Deficient Mice:  A Lupus Model with In... : Shock | AUTOIMMUNITY | Scoop.it
ABSTRACT: Hyper-elevated immune response of FcGRIIb−/− mice, a lupus model with an inhibitory-signal
No comment yet.
Scooped by Gilbert C FAURE
May 6, 2017 8:11 AM
Scoop.it!

Nature, Functions, and Clinical Implications of IgG4 Autoantibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis - Qingjun Pan - Discovery Medicine

Nature, Functions, and Clinical Implications of IgG4 Autoantibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis - Qingjun Pan - Discovery Medicine | AUTOIMMUNITY | Scoop.it
Protective autoantibodies in homeostasis, clinical relevance, and therapeutic potential have gained wide attention. Recent studies showed that IgG4 autoantibodies play crucial roles in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In one aspect, IgG4 autoantibodies can bind autoantigens in .
No comment yet.
Scooped by Gilbert C FAURE
April 30, 2017 3:40 AM
Scoop.it!

Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus

Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus | AUTOIMMUNITY | Scoop.it
Effector CD8+ T cell function is impaired in systemic lupus erythematosus (SLE) and is associated with a compromised ability to fight infections. Signaling lymphocytic activation molecule famil
No comment yet.
Scooped by Gilbert C FAURE
April 3, 2017 1:43 PM
Scoop.it!

Slideshow: A Visual Guide to Lupus

Slideshow: A Visual Guide to Lupus | AUTOIMMUNITY | Scoop.it
Lupus symptoms, skin rashes, joint pain, causes, diagnosis, and treatments are explained with pictures in this slideshow from WebMD's medical editors.
No comment yet.
Scooped by Gilbert C FAURE
March 28, 2017 3:55 AM
Scoop.it!

Lupus Science & Medicine: 4 (Suppl 1)

Lupus Science & Medicine: 4 (Suppl 1) | AUTOIMMUNITY | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
March 23, 2017 2:59 AM
Scoop.it!

Filière des maladies Auto Immunes et Auto Inflammatoires Rares FAI²R

Filière des maladies Auto Immunes et Auto Inflammatoires Rares FAI²R | AUTOIMMUNITY | Scoop.it
• Actu PNDS •

Nous avons le plaisir de vous annoncer la mise en ligne de l'actualisation du PNDS LUPUS sur le site de l'HAS !

Pour l
Gilbert C FAURE's insight:
à lire
No comment yet.
Scooped by Gilbert C FAURE
March 1, 2017 4:42 AM
Scoop.it!

F1000Research Article: Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective?.

Tertiary lymphoid organs are found at sites of chronic inflammation in autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. These organized accumulations of T and B cells resemble secondary lymphoid organs and generate autoreactive effector cells. However, whether they contribute to disease pathogenesis or have protective functions is unclear. Here, we discuss how tertiary lymphoid organs can generate potentially pathogenic cells but may also limit the extent of the response and damage in autoimmune disease.
No comment yet.
Scooped by Gilbert C FAURE
January 19, 2017 12:16 PM
Scoop.it!

Systemic lupus erythematosus: New pathway blocks disease in lupus-prone mice

Nature Reviews Rheumatology | doi:10.1038/nrrheum.2017.2
No comment yet.
Scooped by Gilbert C FAURE
January 7, 2017 1:05 PM
Scoop.it!

Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE

Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE | AUTOIMMUNITY | Scoop.it
Plasmablasts and plasma cells (PBs and PCs) producing pathogenic auto-antibodies in patients with systemic autoimmune diseases could be a better target for specific therapies for the disease than general immunosuppression or pan- or activated B-cell targeting. Our previous study indicated that leukocyte immunoglobulin-like receptor (LILR) B4 (B4, also known as ILT3/LIR-5/CD85k), a tolerogenic receptor in antigen-presenting cells, is ectopically expressed on the PB/PC surface in healthy individuals. Here, we show that the enlarged population size of PBs/PCs with augmented B4 expression is characteristic in non-treated systemic lupus erythematosus (SLE). Paradoxically, the transcription frequency of the anti-double-strand DNA immunoglobulin-coding VH sequence in the B4+ population of non-treated SLE was significantly higher than that in B4– cells. B4+ and B4– PBs/PCs were suggested to be developmentally equivalent based on the simultaneous generation of these populations upon activation of memory B cells in vitro. B4 expression was found to be induced efficiently by IL-2, while IFN-α effectively induced B4+ PBs/PCs in vitro. Utilizing the elevated B4 will support opening a new avenue for identifying the mechanism for generation of, and additional molecular markers for, pathogenic cells.
No comment yet.
Scooped by Gilbert C FAURE
January 5, 2017 4:09 AM
Scoop.it!

TGF-β3 Inhibits Antibody Production by Human B Cells

TGF-β3 Inhibits Antibody Production by Human B Cells | AUTOIMMUNITY | Scoop.it
TGF-β is a pleotropic cytokine involved in various biological processes. Of the three isoforms of TGF-β, TGF-β1 has long been recognized as an important inhibitory cytokine in the immune system and has been reported to inhibit B cell function in both mice and humans. Recently, it has been suggested that TGF-β3 may play an important role in the regulation of immune system in mice. Murine CD4+CD25-LAG3+ regulatory T cells suppress B cell function through the production of TGF-β3, and it has been reported that TGF-β3 is therapeutic in a mouse model of systemic lupus erythematosus. The effect of TGF-β3 on human B cells has not been reported, and we herein examined the effect of TGF-β3 on human B cells. TGF-β3 suppressed B cell survival, proliferation, differentiation into plasmablasts, and antibody secretion. Although the suppression of human B cells by TGF-β1 has long been recognized, the precise mechanism for the suppression of B cell function by TGF-β1 remains elusive; therefore, we examined the effect of TGF-β1 and β3 on pathways important in B cell activation and differentiation. TGF-β1 and TGF-β3 inhibited some of the key molecules of the cell cycle, as well as transcription factors important in B cell differentiation into antibody secreting cells such as IRF4, Blimp-1, and XBP1. TGF-β1 and β3 also inhibited B cell receptor signaling. Our results suggest that TGF-β3 modifying therapy might be therapeutic in autoimmune diseases with B cell dysregulation in humans.
No comment yet.
Scooped by Gilbert C FAURE
January 3, 2017 8:16 AM
Scoop.it!

Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus

Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus | AUTOIMMUNITY | Scoop.it
Interleukin-34 (IL-34) was initially identified as an alternative ligand for the colony-stimulating factor-1 receptor (CSF-1R) to mediate the biology of mononuclear phagocytic cells. Recently, IL-34 was found to be associated with chronic inflammation, such as in rheumatoid arthritis (RA). Both RA and systemic lupus erythematosus (SLE) are multifactorial autoimmune diseases and are characterized by excessive immune and inflammatory responses. Thus, we investigated whether IL-34 is involved in the pathogenesis of SLE. In all, 78 SLE patients and 53 healthy controls were enrolled in the research. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the concentrations of serological IL-34. Then serum IL-34 levels between the SLE group and healthy controls were analyzed by the Mann-Whitney U test. Meanwhile, the correlations between the serum IL-34 levels and disease activity indexes and other established serum markers were assessed. Furthermore, the serum IL-34 levels of 20 active SLE patients were reevaluated when diseases were in the remission stage from corticosteroids or immunosuppressive drugs. Serum IL-34 levels were significantly higher in SLE patients compared to healthy controls. Their levels were remarkably associated with accumulation of the clinical features of SLE. Additionally, IL-34 titers were positively correlated with the SLE disease activity indexes, anti-double-stranded DNA antibody (anti-dsDNA) titers and C-reactive protein (CRP) levels, and inversely with complement3 (C3) levels. Moreover, serum IL-34 levels were significantly decreased after successful treatment of SLE. Serum IL-34 could be a candidate biomarker for SLE as there are elevated serum levels in treatment-naive SLE patients and we saw a significant decrease after effective treatment.
No comment yet.
Scooped by Gilbert C FAURE
June 3, 2017 3:42 PM
Scoop.it!

Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus

Objective SLE is traditionally classified using the American College of Rheumatology (ACR) criteria. The Systemic Lupus International Collaborating Clinics (SLICC) recently validated an alternative system. This study examined large cohorts of subjects with SLE and incomplete lupus erythematosus (ILE) to compare the impact of ACR and SLICC criteria.

Methods Medical records of subjects in the Lupus Family Registry and Repository were reviewed for documentation of 1997 ACR classification criteria, SLICC classification criteria and medication usage. Autoantibodies were assessed by indirect immunofluorescence (ANA, antidouble-stranded DNA), precipitin (Sm) and ELISA (anticardiolipin). Other relevant autoantibodies were detected by precipitin and with a bead-based multiplex assay.

Results Of 3575 subjects classified with SLE under at least one system, 3312 (92.6%) were classified as SLE by both systems (SLEboth), 85 only by ACR criteria (SLEACR-only) and 178 only by SLICC criteria (SLESLICC-only). Of 440 subjects meeting 3 ACR criteria, 33.9% (149/440) were SLESLICC-only, while 66.1% (n=291, designated ILE) did not meet the SLICC classification criteria. Under the SLICC system, the complement criterion and the individual autoantibody criteria enabled SLE classification of SLESLICC-only subjects, while SLEACR-only subjects failed to meet SLICC classification due to the combined acute/subacute cutaneous criterion. The SLICC criteria classified more African-American subjects by the leucopenia/lymphopenia criterion than did ACR criteria. Compared with SLEACR-only subjects, SLESLICC-only subjects exhibited similar numbers of affected organ systems, rates of major organ system involvement (∼30%: pulmonary, cardiovascular, renal, neurological) and medication history.

Conclusions The SLICC criteria classify more subjects with SLE than ACR criteria; however, individuals with incomplete lupus still exist under SLICC criteria. Subjects who gain SLE classification through SLICC criteria exhibit heterogeneous disease, including potential major organ involvement. These results provide supportive evidence that SLICC criteria may be more inclusive of SLE subjects for clinical studies.
No comment yet.
Scooped by Gilbert C FAURE
May 25, 2017 1:49 PM
Scoop.it!

Antinuclear antibody testing misunderstood or misbegotten? : Nature Reviews Rheumatology : Nature Research

Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that recognize nuclear macromolecules and their complexes. ANAs represent key biomarkers in the evaluation of rheumatic diseases, most prominently systemic lupus erythematosus (SLE), and ANA testing is commonly performed in the clinical setting. In addition, ANA testing is now used to assess eligibility for participation in clinical trials of new therapeutic agents for SLE. ANAs can be assayed by various techniques, with the fluorescent ANA assay often viewed as the gold standard. Whereas a positive ANA test represents a classification criterion for SLE, up to 20–30% of the healthy population, depending on the assay used, is positive for an ANA, complicating the use of this test for diagnosis or the detection of preclinical autoimmunity. Furthermore, ANAs might be expressed in SLE less commonly than often thought. This Perspectives article discusses important questions about the use of ANA testing in both the clinical and research settings.
No comment yet.
Scooped by Gilbert C FAURE
May 14, 2017 12:36 PM
Scoop.it!

Cellular & Molecular Immunology - The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus

Cellular & Molecular Immunology - The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus | AUTOIMMUNITY | Scoop.it
Cellular and Molecular Immunology aims to report the dynamic progress being made in China and abroad in immunological research, and welcomes high-quality Research Articles, Reviews and Brief Reports across a broad range of topics including, but not limited to, clinical immunology, comparative immunology, immunobiology, immunogenetics, immunological techniques, immunopathology, immunopharmacology, infection immunology, neuroimmunology, transplantation immunology, tumor immunology, and veterinary immunology.
No comment yet.
Scooped by Gilbert C FAURE
May 5, 2017 4:49 AM
Scoop.it!

Autoimmune choreas

Autoimmune choreas | AUTOIMMUNITY | Scoop.it
Chorea, a movement disorder characterised by a continuous flow of unpredictable muscle contractions, has a myriad of genetic and non-genetic causes. Although autoimmune processes are rare aetiology of chorea, they are relevant both for researchers and clinicians. The aim of this article is to provide a review of the epidemiology, clinical and laboratory features, pathogenesis and management of the most common autoimmune causes of chorea. Emphasis is given particularly to Sydenham's chorea, systemic lupus erythematosus, primary antiphospolipid antibody syndrome, paraneoplastic chorea and anti- N -methyl-d-aspartate receptor encephalitis.
No comment yet.
Scooped by Gilbert C FAURE
April 4, 2017 4:08 AM
Scoop.it!

Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial

Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial | AUTOIMMUNITY | Scoop.it
To assess the efficacy and tolerability of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE), in a phase III clinical trial conducted in Japan.We conducted a double‐blind
No comment yet.
Scooped by Gilbert C FAURE
March 30, 2017 3:12 PM
Scoop.it!

F1000Research Article: B-cell tolerance and autoimmunity.

Self-reactive B cells are tolerized at various stages of B-cell development and differentiation, including the immature B-cell stage (central tolerance) and the germinal center (GC) B-cell stage, and B-cell tolerance involves various mechanisms such as deletion, anergy, and receptor editing. Self-reactive B cells generated by random immunoglobulin variable gene rearrangements are tolerized by central tolerance and anergy in the periphery, and these processes involve apoptosis regulated by Bim, a pro-apoptotic member of the Bcl-2 family, and regulation of B-cell signaling by various phosphatases, including SHIP-1 and SHP-1. Self-reactive B cells generated by somatic mutations during GC reaction are also eliminated. Fas is not directly involved in this process but prevents persistence of GC reaction that allows generation of less stringently regulated B cells, including self-reactive B cells. Defects in self-tolerance preferentially cause lupus-like disease with production o
No comment yet.
Scooped by Gilbert C FAURE
March 27, 2017 2:19 AM
Scoop.it!

What is damaging the kidney in lupus nephritis? : Nature Reviews Rheumatology : Nature Research

What is damaging the kidney in lupus nephritis? : Nature Reviews Rheumatology : Nature Research | AUTOIMMUNITY | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
March 12, 2017 1:48 AM
Scoop.it!

Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients

Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients | AUTOIMMUNITY | Scoop.it
Internal Medicine Article: Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients
No comment yet.
Scooped by Gilbert C FAURE
January 25, 2017 12:34 PM
Scoop.it!

UPDATE: From Lupus to a Vaccine for Diabetes Type I? Dates Announced

UPDATE: From Lupus to a Vaccine for Diabetes Type I? Dates Announced | AUTOIMMUNITY | Scoop.it
The European Biotech News Website
Gilbert C FAURE's insight:
Neovacs pipeline
No comment yet.
Scooped by Gilbert C FAURE
January 11, 2017 1:12 PM
Scoop.it!

Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome

Objectives
Patients with antiphospholipid syndrome (APS) are at risk for subclinical endothelial injury, as well as accelerated atherosclerosis. In the related disease systemic lupus erythematosus, there is a well-established defect in circulating endothelial progenitors, which leads to an accrual of endothelial damage over time. This defect has been at least partially attributed to exaggerated expression of type I interferons (IFNs). We sought to determine whether these pathways are important in APS.
Methods
We studied 68 patients with primary APS. Endothelial progenitors were assessed by flow cytometry and functional assay. Type I IFN activity was determined by a well-accepted bioassay, while peripheral blood mononuclear cells were scored for expression of IFN-responsive genes.
Results
Endothelial progenitors from patients with APS demonstrated a marked defect in the ability to differentiate into endothelial cells, a phenotype which could be mimicked by treating control progenitors with APS sera. Elevated type I IFN activity was detected in the circulation of patients with APS (a finding that was then replicated in an independent cohort). While IgG depletion from APS sera did not rescue endothelial progenitor function, the dysfunction was successfully reversed by a type I IFN receptor-neutralising antibody.
Conclusions
We describe, for the first time to our knowledge, an IFN signature in primary APS and show that this promotes impaired endothelial progenitor function. This work opens the door to novel approaches that may mitigate vascular damage in APS, such as anti-IFN drugs.
No comment yet.
Scooped by Gilbert C FAURE
January 6, 2017 9:14 AM
Scoop.it!

Death receptor 6 contributes to autoimmunity in lupus-prone mice. - PubMed - NCBI

Death receptor 6 contributes to autoimmunity in lupus-prone mice. - PubMed - NCBI | AUTOIMMUNITY | Scoop.it
Nat Commun. 2017 Jan 3;8:13957. doi: 10.1038/ncomms13957.
No comment yet.
Scooped by Gilbert C FAURE
January 3, 2017 8:18 AM
Scoop.it!

Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus

Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus | AUTOIMMUNITY | Scoop.it
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs and tissues, which is characterized by the presence of excessive anti-nuclear autoantibodies. The pathogenesis of SLE has been intensively studied but remains far from clear. Increasing evidence has shown that the genetic susceptibilities and environmental factors-induced abnormalities in immune cells, dysregulation of apoptosis, and defects in the clearance of apoptotic materials contribute to the development of SLE. As the main source of auto-antigens, aberrant cell death may play a critical role in the pathogenesis of SLE. In this review, we summarize up-to-date research progress on different levels of cell death—including increasing rate of apoptosis, necrosis, autophagy and defects in clearance of dying cells—and discuss the possible underlying mechanisms, especially epigenetic modifications, which may provide new insight in the potential development of therapeutic strategies for SLE.
No comment yet.